

Prepared by: Alliance for Cancer Gene Therapy (ACGT)
acgtfoundation.org

Contact: Jenifer Howard | JHPR
jhoward@jhowardpr.com
203-273-4246

For Immediate Release

**Alliance for Cancer Gene Therapy (ACGT)
Announces New Board Member**
*Chau Q. Khuong Joins ACGT Board of Directors and Brings
Additional Venture Capital and Bio/Pharma Expertise*

STAMFORD, Conn., May 25, 2016 -- **Alliance for Cancer Gene Therapy (ACGT)**, the nation's only nonprofit dedicated exclusively to cell and gene therapies for cancer, is pleased to announce the addition of **Chau Q. Khuong** to its Board of Directors. Mr. Khuong, who is based in New York City, brings his expertise in healthcare venture capital to the nonprofit.

Mr. Khuong is interested in addressing problems in human health through the application and commercialization of innovative scientific discovery. His work with ACGT will involve Board oversight of the Scientific Advisory Council and the selection process of ACGT grant recipients for both clinical and discovery cancer research. His venture capital experience will also be instrumental as more of the nonprofit's relationships are beginning to build with the VC and bio/pharma industries.

ACGT has reached many milestones during the past 15 years, funding 50 scientific grants in the U.S. and Canada, which have been focused on accelerating critically needed innovative cancer research. Since its inception, ACGT has awarded 34 grants to Young Investigators and 16 grants to Clinical Investigators, totaling more than \$26.4 million in funding. ACGT was one of the initial funding partners for the pilot program on the breakthrough cancer research to successfully treat leukemia through gene therapy pioneered by Dr. Carl June at the University of Pennsylvania and Dr. Michel Sadelain at Memorial Sloan Kettering. This work has been touted in recent national documentaries on cancer on PBS and HBO featuring several ACGT scientists.

"As ACGT expands its funding of critical cancer research, partnerships and strategic Board members such as Chau Khuong are crucial to the success of moving the needle forward in treating cancer," noted John Walter, CEO and president of ACGT. "We are privileged to have Mr. Khuong join ACGT and look forward to an exciting future of breakthroughs in treating cancer."

Khuong joins ACGT's 15 other Board of Director members, bringing the total to 16. ACGT also has a 16 member Scientific Advisory Council comprised of leading cancer scientists in North America.

"I'm very pleased to join the Alliance for Cancer Gene Therapy's Board and help direct this innovative organization as it seeks out the science that has the most potential to effectively treat cancer," said Mr. Khuong. "We are at a turning point in the treatment of cancer and ACGT is leading the way with lifesaving discoveries."

Chau Q. Khuong is a partner in the private equity group OrbiMed Advisors, a global healthcare-dedicated investment firm with approximately \$15 billion in assets under management. During his career, Mr. Khuong has been an active lead investor in innovative drug development and medical device enterprises, across all stages and numerous therapeutic areas including oncology, infectious diseases, ophthalmology, gene editing, and the microbiome. He currently serves as a Board director of several public and private companies, including Aerpio Therapeutics Inc., Cerapedics, Inspire Medical Systems, Intellia, Nabriva (NASDAQ: NBVR), NextCure, Otonomy, Inc. (NASDAQ: OTIC), Pieris Pharmaceuticals (NASDAQ: PIRS), ReViral Ltd, and Synlogic. He holds a B.S. in molecular, cellular and developmental biology with concentration in biotechnology and a MPH with concentration in infectious diseases, both from Yale University.

About Alliance for Cancer Gene Therapy (ACGT)

Established in 2001, ACGT is the nation's only non-profit dedicated exclusively to cell and gene therapy treatments for all types of cancer. One hundred percent of contributions go directly to research. ACGT has funded 50 grants in the U.S. and Canada since its founding in 2001 by Barbara Netter and her late husband Edward, to conduct and accelerate critically needed innovative research. Since its inception, ACGT has awarded 34 grants to Young Investigators and 16 grants to Clinical Investigators, totaling more than \$26.4 million in funding. ACGT is located at 96 Cummings Point Road, Stamford, Connecticut 06902; 203-358-5055. To learn more, visit acgtfoundation.org or join the ACGT community on Facebook, Twitter and YouTube at [@acgtfoundation](https://www.facebook.com/acgtfoundation).

###



Chau Q. Khuong, new member of the Board of the Alliance of Cancer Gene Therapy (ACGT), the nation's only non-profit dedicated to cancer cell and gene therapy research - acgtfoundation.org.